Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. If you experience sudden vision changes, floating spots, flashes of light, or vision loss, seek immediate medical attention.

Diabetic Retinopathy: Protecting Your Vision

Creator: Editorial Team
Published: 2026-03-28

Last updated: March 2026 | Reviewed by MDTalks Editorial Team

Diabetic retinopathy is the leading cause of new blindness in working-age adults in the United States. It occurs when chronically elevated blood sugar damages the tiny blood vessels in the retina, the light-sensitive tissue at the back of the eye. The condition often has no symptoms in its early stages, which is why regular eye screening is critical for every person with diabetes.

The encouraging news: early detection through routine screening, combined with intensive glucose and blood pressure management, can prevent or delay vision loss in the vast majority of cases.

How Diabetic Retinopathy Develops

Chronic hyperglycemia damages the walls of retinal blood vessels, making them leak fluid, swell, or close off entirely. The retina may then grow new, abnormal blood vessels (neovascularization) that are fragile and prone to bleeding. The progression typically follows predictable stages:

Non-Proliferative Diabetic Retinopathy (NPDR)

The early stage. Small areas of swelling (microaneurysms) form in the retinal blood vessels. As NPDR progresses:

Mild NPDR: Few microaneurysms present
Moderate NPDR: Blood vessels that nourish the retina swell and distort, losing their ability to transport blood
Severe NPDR: Many blood vessels are blocked, depriving areas of the retina of blood supply. The retina signals the body to grow new vessels.

Proliferative Diabetic Retinopathy (PDR)

The advanced stage. New blood vessels grow along the retina and into the vitreous gel. These new vessels are fragile and can leak blood into the eye (vitreous hemorrhage), causing sudden vision loss. Scar tissue from these vessels can also pull the retina away from the back of the eye (tractional retinal detachment).

Diabetic Macular Edema (DME)

Fluid leaks into the macula, the central part of the retina responsible for sharp, straight-ahead vision. DME can occur at any stage of retinopathy and is the most common cause of vision loss in people with diabetic retinopathy.

Risk Factors

Factor	Impact
Duration of diabetes	Risk increases with years since diagnosis
Poor glycemic control	Higher A1C = higher risk
Hypertension	Accelerates retinal vascular damage
Dyslipidemia	Contributes to vascular changes
Pregnancy	Can accelerate retinopathy progression
Nephropathy	Strong interrelationship; presence of one increases risk of the other
Smoking	Impairs vascular health

Screening Recommendations

The 2026 ADA Standards of Care recommend:

Diabetes Type	Initial Eye Exam	Follow-Up
Type 1	Within 5 years of diagnosis	Annually (every 1–2 years if no retinopathy and stable A1C)
Type 2	At the time of diagnosis	Annually (every 1–2 years if no retinopathy and stable A1C)
Gestational diabetes	Not required for GDM specifically	Women with pre-existing diabetes should be examined before pregnancy or in the first trimester

Exams should be dilated and comprehensive, performed by an ophthalmologist or optometrist experienced in diabetic eye disease. AI-assisted retinal imaging is increasingly used as a screening tool in primary care settings, though it does not replace comprehensive eye examination.

For related screening information, see Diabetic Neuropathy: Symptoms, Prevention, Treatment and What Is A1C? Understanding Your Average Blood Sugar.

Prevention

Intensive diabetes management is the most effective strategy for preventing retinopathy:

Glycemic control: Large prospective studies (DCCT for type 1, UKPDS for type 2) demonstrated that intensive glucose control reduces the risk of retinopathy onset by 35%–76% and slows progression significantly.
Blood pressure control: The 2026 ADA Standards encourage a systolic blood pressure target below 120 mmHg for patients with high cardiovascular or kidney risk. Blood pressure management independently reduces retinopathy risk.
Lipid management: Treating dyslipidemia may reduce hard exudates and slow disease progression.
Smoking cessation: Improves overall vascular health.

Treatment

For NPDR

Optimize glycemic and blood pressure control
Monitor with regular eye exams (frequency determined by severity)
No ocular intervention needed for mild to moderate NPDR without DME

For PDR

Pan-retinal photocoagulation (PRP): Laser treatment to shrink abnormal blood vessels and reduce the risk of severe vision loss
Anti-VEGF injections: Medications (ranibizumab, aflibercept, bevacizumab) injected into the eye to reduce neovascularization and macular edema. Now considered first-line for many cases.
Vitrectomy: Surgical removal of vitreous gel and blood in cases of severe vitreous hemorrhage or retinal detachment

For DME

Anti-VEGF injections: First-line treatment; significantly improves vision in many patients
Focal/grid laser therapy: Used when anti-VEGF is insufficient or unavailable
Corticosteroid implants: For cases resistant to anti-VEGF therapy

Early treatment is far more effective than late intervention. This is why screening before symptoms appear is so important.

For the full diabetes management perspective, see the Complete Guide to Diabetes Management in 2026.

Key Takeaways

Diabetic retinopathy is the leading cause of blindness in working-age adults but is largely preventable with early detection and treatment.
Regular dilated eye exams are essential: at diagnosis for type 2, within 5 years for type 1, and annually thereafter.
Intensive glucose and blood pressure control reduce the risk of retinopathy onset and slow its progression.
Anti-VEGF injections have transformed treatment and can preserve or restore vision when administered early.
If you experience sudden vision changes, floating spots, flashes of light, or dark areas in your vision, seek immediate medical attention.
Consult your healthcare provider to ensure you are on a regular screening schedule.

Sources

American Diabetes Association. “12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes — 2026.” Diabetes Care, January 2026. pmc.ncbi.nlm.nih.gov
National Eye Institute. “Diabetic Retinopathy.” nei.nih.gov
Centers for Disease Control and Prevention. “Diabetes and Vision Loss.” cdc.gov

This article is part of the MDTalks Diabetes Hub. See also AI Answers About Diabetes and AI Answers About Glaucoma.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider for eye care and diabetes management.